Core Viewpoint - Wohuah Pharmaceutical reported strong financial results for 2025, with revenue of 817 million yuan, a year-on-year increase of 6.96%, and a net profit of 95.72 million yuan, a significant increase of 162.93% [1][2]. However, the company is entering a "no actual controller" era due to a divorce-related equity dispute involving its major shareholder [3]. Financial Performance - The company achieved a revenue of 817 million yuan in 2025, reflecting a growth of 6.96% year-on-year [1]. - The net profit reached 95.72 million yuan, marking a substantial increase of 162.93% compared to the previous year [1]. - The basic earnings per share were reported at 0.17 yuan, with a cash dividend of 1.46 yuan per 10 shares [1]. - The company's non-recurring net profit increased by 168.20% [1]. Product and Market Strategy - Wohuah Pharmaceutical has four major proprietary products that serve as its core revenue drivers, generating 569 million yuan in revenue, a growth of 12.31% year-on-year, with a gross margin of 83.43% [2]. - The company is transitioning its marketing strategy to enhance sales, focusing on both hospital and outpatient markets, establishing a "hospital + outpatient" collaborative development model [2]. - The revenue from the outpatient market, including e-commerce and OTC sales, reached approximately 103 million yuan, accounting for 12.6% of total revenue, with e-commerce sales increasing by 113% year-on-year [2]. Governance Changes - Wohuah Pharmaceutical has entered a "no actual controller" status due to a court ruling that split the equity of its controlling shareholder, Beijing Zhongzheng Wanrong Investment Group, between the former couple Zhao Bingxian and Lu Juan [3]. - The company has implemented significant reforms in its governance structure since July 2020, establishing a "board-centered" governance model that empowers the board with the highest decision-making and supervisory authority [4]. - The board has adapted to the new governance landscape, ensuring rapid response and decision-making to external market challenges, maintaining stability despite the lack of a controlling shareholder [4].

Core Viewpoint - A long-standing divorce property dispute involving significant assets and control of a listed company has concluded, resulting in a change of actual control over Wohuamedicine [1][3]. Company Control Change - The court's ruling mandates an equal division of shares in Zhongzheng Wanrong Investment Group, the controlling shareholder of Wohuamedicine, between Zhao Bingxian and his ex-wife Lu Juan, changing the actual control of Wohuamedicine to a state of no actual controller [3][12]. - Zhao Bingxian previously held 80% of Zhongzheng Wanrong, while Lu Juan held 20%. Post-division, both will hold 50% each [3][12]. - The value of the shares transferred to Lu Juan is approximately 547 million yuan, based on Wohuamedicine's market capitalization of 3.648 billion yuan as of November 10, 2025 [3][12]. Company Background - Wohuamedicine, established in 2002 and listed in 2007, specializes in the research, production, and sales of natural plant-based cardiovascular traditional Chinese medicine [12]. - The company's core products include Wohuaxin Keshupian, Gushukang capsules/particles, Huo Dan tablets/capsules, and Naoxue Shukouye, which are the main sources of its revenue and profit [12]. Financial Performance - Wohuamedicine has faced declining performance in recent years, with a continuous drop in net profit from 2021 to 2024 due to price reductions of core products and high marketing costs [12][13]. - The revenue from Wohuaxin Keshupian decreased by 22.56% in 2024, significantly impacting overall revenue [13]. - However, there was a turnaround in 2025, with a reported revenue of 625 million yuan, an increase of 8.31%, and a net profit of 63.995 million yuan, up 179.34% year-on-year [13]. Shareholder Dynamics - The number of shareholders in Wohuamedicine decreased from 48,021 to 34,476 between Q1 2021 and Q1 2025, but began to stabilize and increase to 41,003 by September 30, 2025 [13]. - Following the court ruling, Wohuamedicine's stock price remained stable, with slight increases observed after the announcement [14]. Future Outlook - Lu Juan expressed her commitment to improving management and governance within the company, emphasizing the importance of a professional management team and internal governance mechanisms for sustainable development [14]. - She plans to convene a shareholders' meeting to discuss the company's governance and development direction [14].

Core Viewpoint - The actual controller of Shandong Wohua Pharmaceutical Technology Co., Ltd. has changed due to a court ruling on a long-standing divorce property dispute, which may impact the company's operations and performance during a critical recovery phase [1][3]. Group 1: Control Change - The change in actual control of Wohua Pharmaceutical stems from a 15-year divorce property dispute between Zhao Bingxian and Lu Juan, which has now concluded with a court ruling [1][3]. - Zhao Bingxian previously held 80% of the shares in Zhongzheng Wanrong Investment Group, the controlling shareholder of Wohua Pharmaceutical, which owned 50.27% of the company [3]. - Following the court's decision, both Zhao and Lu now hold 50% of Zhongzheng Wanrong, resulting in no single party being able to control the company, thus leading to a state of no actual controller [3]. Group 2: Financial Performance - Wohua Pharmaceutical has experienced a decline in revenue and net profit from 2020 to 2024, with revenues of 1.006 billion, 943 million, 1.015 billion, 910 million, and 764 million respectively, reflecting changes of -16.95%, -6.3%, 7.65%, -10.38%, and -16.02% [5]. - The net profit has also decreased significantly, with figures of 179 million, 163 million, 107 million, 58.76 million, and 36.4 million, showing year-on-year changes of -86.72%, -8.66%, -34.28%, -45.27%, and -38.05% [5]. - The decline in core product sales, particularly the Wohua Xinkeshu Pian, which saw a price drop of approximately 39% after entering a centralized procurement range, has been a major factor in the revenue decline [5]. Group 3: Recent Recovery - Wohua Pharmaceutical's performance began to recover in 2025, with a reported revenue of 425 million in the first half, marking a 7.64% increase year-on-year, and a net profit of 44.68 million, up 303.16% [6]. - The third-quarter report for this year indicated revenues of approximately 625 million, an increase of 8.31%, and a net profit of about 63.99 million, up 179.34% [7]. - Despite the recovery, the company continues to face high sales expenses, which accounted for over 50% of revenue, with sales expenses of 471 million, 422 million, 521 million, 492 million, and 389 million from 2020 to 2024 [7].

Core Viewpoint - The court ruling on the property division between Zhao Bingxian and his ex-wife Lu Juan has significant implications for Wohuayi Pharmaceutical, leading to a change in the actual controller of the company and raising concerns about its operational stability and financial performance [1][2][3]. Group 1: Legal and Ownership Changes - The Beijing Third Intermediate People's Court upheld the first-instance ruling, mandating an equal division of shares in Zhongzheng Wanrong Investment Group between Zhao Bingxian and Lu Juan, which affects the control of Wohuayi Pharmaceutical [2][3]. - Following the ruling, Zhao Bingxian's ownership in Zhongzheng Wanrong Investment Group decreased from 80% to 50%, resulting in the company having no actual controller [2][3]. - Despite the legal changes, Zhao Bingxian continues to hold key positions within both Zhongzheng Wanrong Investment Group and Wohuayi Pharmaceutical, ensuring that business operations remain unaffected [2][3]. Group 2: Financial Performance - Wohuayi Pharmaceutical's total market value reached 3.584 billion yuan, with Zhao Bingxian's "divorce settlement" amounting to 540 million yuan based on the court's decision [1][2]. - The company has experienced a decline in revenue and net profit over the past four years, with revenues of 943 million yuan, 1.015 billion yuan, 910 million yuan, and 764 million yuan from 2021 to 2024, reflecting year-on-year changes of -6.30%, 7.65%, -10.38%, and -16.02% respectively [4]. - The net profit attributable to shareholders has also decreased significantly, with figures of 163 million yuan, 107 million yuan, 58.77 million yuan, and 36.40 million yuan during the same period, showing declines of 8.66%, 34.28%, 45.27%, and 38.05% [4]. Group 3: Research and Development - Wohuayi Pharmaceutical has not introduced any new drug approvals or unique products in over five years, relying on existing products for revenue generation [7]. - The company reported a sales expense to revenue ratio of approximately 52% in the first three quarters of 2025, which is about 12 times its research and development expenses [9]. - Sales expenses from 2021 to 2024 were 422 million yuan, 521 million yuan, 492 million yuan, and 389 million yuan, with a notable increase in 2025's first three quarters to 322 million yuan, reflecting a year-on-year growth of 6.47% [8][9].

Core Viewpoint - The court ruling on the divorce property dispute between Zhao Bingxian and Lu Juan results in a change of actual control of WoHua Pharmaceutical, as the couple will each hold 50% of the shares in the controlling shareholder, Zhongzheng Wanrong Investment Group, leading to the absence of an actual controller for the company [1] Group 1 - The Beijing Third Intermediate People's Court upheld the first-instance ruling regarding the division of shares held by Zhao Bingxian and Lu Juan in Zhongzheng Wanrong Investment Group [1] - The ruling only pertains to the division of shares between Zhao Bingxian and Lu Juan and does not affect Zhongzheng Wanrong Investment Group's 50.27% stake in WoHua Pharmaceutical [1] - The outcome of the ruling results in a change of actual control from Zhao Bingxian to no actual controller for WoHua Pharmaceutical [1]

Core Viewpoint - The Beijing Third Intermediate People's Court has upheld a second-instance ruling regarding the property dispute between Zhao Bingxian and Lu Juan, resulting in an equal division of their shares in Zhongzheng Wanrong Investment Group, which is the controlling shareholder of WoHua Pharmaceutical [1] Group 1: Legal Proceedings - The court's decision maintains the first-instance ruling from the Tongzhou District People's Court, which mandates that Zhao Bingxian and Lu Juan split their shares in Zhongzheng Wanrong Investment Group equally [1] - The ruling specifically pertains to the shares held by Zhao Bingxian and Lu Juan in Zhongzheng Wanrong Investment Group and does not affect the group's 50.27% stake in WoHua Pharmaceutical [1] Group 2: Impact on Company Control - The outcome of the court ruling results in Zhao Bingxian and Lu Juan each holding 50% of Zhongzheng Wanrong Investment Group, leading to a change in the actual controller of WoHua Pharmaceutical [1] - Following the ruling, the actual controller of WoHua Pharmaceutical transitions from Zhao Bingxian to a state of no actual controller [1]

Core Viewpoint - The Beijing Third Intermediate People's Court has upheld a second-instance ruling regarding the property dispute between Zhao Bingxian and Lu Juan, resulting in an equal division of their shares in Zhongzheng Wanrong Investment Group, which is the controlling shareholder of WoHua Pharmaceutical [1] Group 1: Legal Proceedings - The court's ruling maintains the first-instance decision from the Tongzhou District People's Court, confirming that Zhao Bingxian and Lu Juan will each hold 50% of Zhongzheng Wanrong Investment Group's shares [1] - The ruling specifically pertains to the division of shares held by Zhao Bingxian and Lu Juan and does not affect Zhongzheng Wanrong Investment Group's 50.27% stake in WoHua Pharmaceutical [1] Group 2: Impact on Company Control - The outcome of the court ruling results in a change in the actual controller of WoHua Pharmaceutical, shifting from Zhao Bingxian to a state of no actual controller [1]

Company Overview - Wohuah Pharmaceutical, established on February 9, 2002, and listed on the Shenzhen Stock Exchange on January 24, 2007, specializes in pure natural plant-based cardiovascular traditional Chinese medicine [1] - The company is headquartered in Weifang, Shandong Province, and its main business includes the research, production, and sales of pure natural plant-based cardiovascular traditional Chinese medicine [1] Financial Performance - For Q3 2025, Wohuah Pharmaceutical reported revenue of 625 million yuan, ranking 53rd out of 69 in the industry, significantly lower than the top competitors, Baiyunshan (61.606 billion yuan) and Yunnan Baiyao (30.654 billion yuan) [2] - The company's net profit for the same period was 58.97 million yuan, ranking 41st in the industry, again trailing behind Yunnan Baiyao (4.789 billion yuan) and Baiyunshan (3.398 billion yuan) [2] Profitability and Debt Management - As of Q3 2025, Wohuah Pharmaceutical's debt-to-asset ratio was 27.21%, a slight decrease from 27.97% year-on-year, and lower than the industry average of 32.81% [3] - The gross profit margin for the same period was 75.12%, an increase from 72.27% year-on-year, and higher than the industry average of 52.44% [3] Leadership - The chairman, Zhao Bingxian, has been in office for over 20 years and has extensive experience in investment [4] - The president, Li Shengtian, has been with the company since March 2001, and his salary decreased from 684,000 yuan in 2023 to 456,000 yuan in 2024 [4] Shareholder Information - As of September 30, 2025, the number of A-share shareholders increased by 17.18% to 41,000, while the average number of shares held per shareholder decreased by 14.66% to 13,900 [5] - New major shareholders include Baodao Jiuhang Mixed A and Guotai Haitong Zhongzheng 500 Index Enhanced A, while Baodao Yuanhang Mixed A exited the top ten list [5]

一、主要会计数据和财务指标 | 报告期指标 | 2025年一季报 | 2024年一季报 | 本年比上年增减(%) | 2023年一季报 | | --- | --- | --- | --- | --- | | 基本每股收益（元） | 0.0400 | 0.0200 | 100 | 0.0400 | | 每股净资产（元） | 1.25 | 1.41 | -11.35 | 1.34 | | 每股公积金(元) | 0 | 0 | 0 | 0 | | 每股未分配利润(元) | 0.17 | 0.34 | -50 | 0.27 | | 每股经营现金流(元) | - | - | - | - | | 营业收入(亿元) | 2.18 | 2.15 | 1.4 | 2.35 | | 净利润(亿元) | 0.23 | 0.1 | 130 | 0.25 | | 净资产收益率(%) | 3.23 | 1.19 | 171.43 | 3.35 | 数据四舍五入，查看更多财务数据>> 二、前10名无限售条件股东持股情况 前十大流通股东累计持有： 31205.64万股，累计占流通股比： 54.78%，较上期变化： 27.53万股。 | 名称 ...